Globus Medical Slides After Full-Year Revenue Guidance Held Steady

Dow Jones

05/09

By Christopher Kuo

Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue.

The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date.

The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion.

The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said.

Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said.

The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier.

Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share.

Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million.

The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share.

(MORE TO FOLLOW) Dow Jones Newswires

May 08, 2026 15:11 ET (19:11 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2634461836"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634461836\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634461836?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 03:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634461836","market":"other","top_or_hot":-1,"title":"Globus Medical Slides After Full-Year Revenue Guidance Held Steady","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue. \n</p>\n<p>\n  The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date. \n</p>\n<p>\n  The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion. \n</p>\n<p>\n  The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said. \n</p>\n<p>\n  Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said. \n</p>\n<p>\n  The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share. \n</p>\n<p>\n  Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million. \n</p>\n<p>\n  The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (MORE TO FOLLOW) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 15:11 ET (19:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Globus Medical Slides After Full-Year Revenue Guidance Held Steady</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobus Medical Slides After Full-Year Revenue Guidance Held Steady\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-09 03:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue. \n</p>\n<p>\n  The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date. \n</p>\n<p>\n  The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion. \n</p>\n<p>\n  The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said. \n</p>\n<p>\n  Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said. \n</p>\n<p>\n  The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share. \n</p>\n<p>\n  Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million. \n</p>\n<p>\n  The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (MORE TO FOLLOW) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 15:11 ET (19:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GMED","symbol_name":"Globus Medical Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634461836","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634461836","pubTimestamp":1778267460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue.The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date.The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion.The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said.Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said.The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier.Adjusted earnings came in at $1.12 a share. Analysts polled by FactSe","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GMED":"Globus Medical Inc"},"translate_title":"Globus Medical在全年收入指引保持稳定后下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMED":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue. \n\n\n  The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date. \n\n\n  The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion. \n\n\n  The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said. \n\n\n  Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said. \n\n\n  The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier. \n\n\n  Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share. \n\n\n  Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million. \n\n\n  The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share. \n\n\n \n\n\n  (MORE TO FOLLOW) Dow Jones Newswires\n\n\n  May 08, 2026 15:11 ET (19:11 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}